fda approves semaglutide obesity drug that helped people cut weight 15% FDA approves obesity drug that

Clinical trial data shows nausea affects approximately 44% of users, diarrhea hits about 30%, and vomiting is common especially during dose escalation

Your weight If you are obese and have a higher body mass index, you may need tirzepatide treatment for a longer time and at higher doses (if your body tolerates it) compared to those with a lower body mass index or those who are a bit overweight

The glucose-dependent mechanism of insulin secretion means that semaglutide carries a lower intrinsic risk of severe hypoglycemia when used as monotherapy, unlike insulin or sulfonylureas

Experts predict the number of people in the U.S